AU StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Tetratherix Ltd

4.000

+0.1904.99%

Volume:10.08K

Turnover:40.33K

Market Cap:203.06M

PE:-13.03

High:4.100

Open:3.980

Low:3.830

Close:3.810

52wk High:5.600

52wk Low:2.880

Shares:50.77M

Float Shares:16.15M

Volume Ratio:1.84

T/O Rate:0.06%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-0.307

EPS(LYR):-0.365

ROE:-150.03%

ROA:-20.10%

PB:8.33

PE(LYR):-10.97

Loading ...

Overview Company News Filings

Tetratherix Says Joint Venture Partner Completes Series A Funding Round to Progress Prostate Spacing Clinical Trial, Shares Jump 5%

MT Newswires Live

Tetratherix Says First Patient Group in Surgical Scar Prevention Product Trial Showed Reduced Scarring; Shares Jump 6%

MT Newswires Live

Tetratherix Up 12%, Insider Buyers Are Up 280%

Simply Wall St.

Tetratherix Ltd-Vecchione Appointment

THOMSON REUTERS

BRIEF-Tetratherix Executes Global Distribution & Supply Agreement With Henry Schein

BUZZ-Australia's Tetratherix hits four-week high on supply deal with Henry Schein

Tetratherix Says Safety Review for Second Patient Group in Surgical Scar Prevention Product Trial Showed No Adverse Events; Shares Jump 5%

MT Newswires Live

Tetratherix Ltd-Director Company Secretary Appointment/Resignation

THOMSON REUTERS

BUZZ-Australia's Tetratherix soars on Alcon funding

BRIEF-Tetratherix Says BioOptix Enters Agreement With Alcon Research

Tetratherix Ltd-Biooptix Alcon Update

THOMSON REUTERS

Tetratherix - Alcon to Provide Milestone-Based Development Funding to Complete Range of Specific Preclinical Studies

THOMSON REUTERS

Tetratherix Says Second Phase of Hydrogel Spacer First In-Human Clinical Investigation Underway

MT Newswires Live

Tetratherix Says Safety Review Committee Confirms No Procedural Related Adverse Events at Trial

MT Newswires Live

Tetratherix Ltd-Tutela Update

THOMSON REUTERS

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/stock/TTX.AU/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"TTX.AU","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:true,,method:\"POST\",data:#items:@#symbol:\"TTX.AU\",,,,,undefined,":{"symbol":"TTX.AU","market":"AU","secType":"STK","nameCN":"Tetratherix Ltd","latestPrice":4,"timestamp":1773119520000,"preClose":3.81,"halted":0,"volume":10084,"delay":0,"changeRate":0.04986876640419946,"nameEN":"Tetratherix Ltd","floatShares":16151799,"shares":50765665,"eps":-0.3071,"marketStatus":"Not Yet Opened","change":0.19,"latestTime":"03-10 16:12:00 AEDT","open":3.98,"high":4.1,"low":3.83,"amount":40332,"amplitude":0.070866,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-0.3071,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":0,"beginTime":1773183600000},"marketStatusCode":0,"adr":0,"listingDate":1751119200000,"exchange":"ASX","adjPreClose":3.81,"openAndCloseTimeList":[[1773097200000,1773118800000]],"volumeRatio":1.8386026328264597,"lotSize":0,"tradeCurrency":"AUD","auctionPricing":{"symbol":"TTX.AU","preClose":3.97,"auctionPrice":3.99,"auctionVolume":1303,"auction":3,"marketStatus":"盘后竞价","timestamp":1772773450083}},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:true,,method:\"POST\",data:#items:@#symbol:\"TTX.AU\",,,,,undefined,":{"symbol":"TTX.AU","floatShares":16151799,"roa":"-20.10%","roe":"-150.03%","lyrEps":-0.364617,"volumeRatio":1.8386026328264597,"shares":50765665,"dividePrice":0,"high":4.1,"amplitude":0.070866,"preClose":3.81,"low":3.83,"week52Low":2.88,"pbRate":"8.33","psRate":"101.65","week52High":5.6,"institutionHeld":0,"latestPrice":4,"eps":-0.3071,"divideRate":0,"volume":10084,"delay":0,"ttmEps":-0.3071,"open":3.98,"prevYearClose":3.28,"prevWeekClose":3.88,"prevMonthClose":3.87,"prevQuarterClose":3.28,"fiveDayClose":3.9,"twentyDayClose":3.79,"sixtyDayClose":3.72},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/TTX.AU\",params:#limit:5,,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"TTX.AU\",market:\"AU\",,,undefined,":[],"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"TTX.AU\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2618600004","title":"Tetratherix Says Joint Venture Partner Completes Series A Funding Round to Progress Prostate Spacing Clinical Trial, Shares Jump 5%","url":"https://stock-news.laohu8.com/highlight/detail?id=2618600004","media":"MT Newswires Live","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618600004?lang=en_us&edition=fundamental","pubTime":"2026-03-10 12:03","pubTimestamp":1773115408,"startTime":"0","endTime":"0","summary":"Tetratherix  said its joint venture partner, Tutelix, completed a Series A funding round from key investors led by a MedTech venture capital firm, bringing the total funds raised by the joint venture to around AU$5 million, allowing the joint venture to fasttrack the prostate spacing clinical trial to move towards an international pivotal study in the Australia and the US, according to a Tuesday Australian bourse filing.The trial was designed to investigate the ability of the Tutelix spacer to be safely injected between the prostate and rectum to create and maintain space around the prostate.Around 12 patients included the Tutelix spacer in their treatment, with the space generated by the spacer reducing the radiation dose received by the rectum in each patient. All 12 participants completed or are in the process of completing their radiation treatment plans.Its shares jumped 5% in recent trading on Tuesday.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["TTX.AU","BK4097","LU2065732104.USD","BK4185","BK7067","PRGS","JYNT"],"gpt_icon":0},{"id":"2612433747","title":"Tetratherix Says First Patient Group in Surgical Scar Prevention Product Trial Showed Reduced Scarring; Shares Jump 6%","url":"https://stock-news.laohu8.com/highlight/detail?id=2612433747","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2612433747?lang=en_us&edition=fundamental","pubTime":"2026-02-17 08:38","pubTimestamp":1771288739,"startTime":"0","endTime":"0","summary":"Tetratherix  said that all patient follow-ups from the first patient group under its clinical study for its TetraDerm product for the potential prevention of scar formation in surgical incisions were completed, showing that the scarring was restricted to 13% at three months and further reduced to 8% after 12 months, according to a Tuesday Australian bourse filing.The one-year follow-up results indicated that when the product is laid between layers of skin tissue before final wound closure, there was negligible scar formation in these patients, with an average Vancouver Scar Scale score of 1.8 out of 13 at three months, decreasing to 1.1 out of 13 at 12 months.The patients underwent skin surgeries with an average wound size of 5.5 centimeters and up to 9 centimeters. The first group was designed to assess scar prevention in incision sites in the trunk and limbs for 12 months after the surgery. The second group is ongoing and is assessing scar formation in face and neck lesions.The firm ","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK7067","TTX.AU"],"gpt_icon":0},{"id":"2605282036","title":"Tetratherix Up 12%, Insider Buyers Are Up 280%","url":"https://stock-news.laohu8.com/highlight/detail?id=2605282036","media":"Simply Wall St.","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2605282036?lang=en_us&edition=fundamental","pubTime":"2026-01-24 07:46","pubTimestamp":1769211982,"startTime":"0","endTime":"0","summary":"Tetratherix Limited ( ASX:TTX ) insiders who purchased shares in the last 12 months were richly rewarded last week. The...","market":"nz","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-ttx/tetratherix-shares/news/tetratherix-up-12-insider-buyers-are-up-280","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-ttx/tetratherix-shares/news/tetratherix-up-12-insider-buyers-are-up-280","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["TTX.AU","BK7067"],"gpt_icon":0},{"id":"2605812351","title":"Tetratherix Ltd-Vecchione Appointment","url":"https://stock-news.laohu8.com/highlight/detail?id=2605812351","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2605812351?lang=en_us&edition=fundamental","pubTime":"2026-01-21 08:47","pubTimestamp":1768956466,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260121:nTUE84JPBB:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7067","TTX.AU"],"gpt_icon":0},{"id":"2604903135","title":"BRIEF-Tetratherix Executes Global Distribution & Supply Agreement With Henry Schein","url":"https://stock-news.laohu8.com/highlight/detail?id=2604903135","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2604903135?lang=en_us&edition=fundamental","pubTime":"2026-01-19 09:08","pubTimestamp":1768784931,"startTime":"0","endTime":"0","summary":"BRIEF-Tetratherix Executes Global Distribution & Supply Agreement With Henry ScheinJan 19 (Reuters) - Tetratherix Ltd TTX.AX:EXECUTES GLOBAL DISTRIBUTION & SUPPLY AGREEMENT WITH HENRY SCHEINFurther company coverage: TTX.AX ((Reuters.Briefs@thomsonreuters.com;))","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260119:nFWN3YI00D:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7067","TTX.AU"],"gpt_icon":0},{"id":"2604990852","title":"BUZZ-Australia's Tetratherix hits four-week high on supply deal with Henry Schein","url":"https://stock-news.laohu8.com/highlight/detail?id=2604990852","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2604990852?lang=en_us&edition=fundamental","pubTime":"2026-01-19 08:18","pubTimestamp":1768781927,"startTime":"0","endTime":"0","summary":"BUZZ-Australia's Tetratherix hits four-week high on supply deal with Henry Schein** Shares of Australia's Tetratherix TTX.AX rise 4.4% to A$3.55, their highest level since December 22** Clinical products co executes global distribution & supply agreement with Henry Schein HSIC.O, a provider of healthcare solutions to office-based dental and medical practitioners ** Says agreement provides a pathway for first Tetratherix product launch in the United States and other major markets** Stock up 8.2% YTD   ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260119:nL6N3YK00U:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","TTX.AU","BK7067","BK4175","BK4585","HSIC"],"gpt_icon":0},{"id":"2603575803","title":"Tetratherix Says Safety Review for Second Patient Group in Surgical Scar Prevention Product Trial Showed No Adverse Events; Shares Jump 5%","url":"https://stock-news.laohu8.com/highlight/detail?id=2603575803","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2603575803?lang=en_us&edition=fundamental","pubTime":"2026-01-13 10:12","pubTimestamp":1768270339,"startTime":"0","endTime":"0","summary":"Tetratherix  said the second safety review of the second patient group in the clinical trial of its TetraDerm product for the potential prevention of scar formation in surgical incisions was completed without any procedural or technical adverse events, according to a Tuesday Australian bourse filing.Nine patients in the second group of the trial successfully completed their six-week follow up assessments, per the filing. Patient recruitment for the third group of the trial has started.The company's shares jumped nearly 5% in recent trading on Tuesday.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["TTX.AU","BK7067"],"gpt_icon":0},{"id":"2591624672","title":"Tetratherix Ltd-Director Company Secretary Appointment/Resignation","url":"https://stock-news.laohu8.com/highlight/detail?id=2591624672","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2591624672?lang=en_us&edition=fundamental","pubTime":"2025-12-16 05:21","pubTimestamp":1765833710,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251215:nTUE3KZYXR:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7067","TTX.AU"],"gpt_icon":0},{"id":"2588523717","title":"BUZZ-Australia's Tetratherix soars on Alcon funding","url":"https://stock-news.laohu8.com/highlight/detail?id=2588523717","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588523717?lang=en_us&edition=fundamental","pubTime":"2025-12-01 10:32","pubTimestamp":1764556375,"startTime":"0","endTime":"0","summary":"BUZZ-Australia's Tetratherix soars on Alcon funding** Shares of Australia's Tetratherix TTX.AX rise as much as 10.1% to A$4.24, their highest level since mid-November** Stock set for its strongest session in six weeks, if current trends hold** Regenerative biomaterials maker says BioOptix, which is co's JV partner has entered agreement with Alcon Research** Under agreement, Alcon Research to provide funding to speed up commercialization of products from Tetramatrix platform technology** Tetramatrix platform technology is a biomaterial platform which creates implantable products for diverse clinical needs - co's website** Stock up near 25% since it listed on June 30  ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251201:nL6N3X703I:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TTX.AU","BK7067"],"gpt_icon":0},{"id":"2588144627","title":"BRIEF-Tetratherix Says BioOptix Enters Agreement With Alcon Research","url":"https://stock-news.laohu8.com/highlight/detail?id=2588144627","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588144627?lang=en_us&edition=fundamental","pubTime":"2025-12-01 09:38","pubTimestamp":1764553123,"startTime":"0","endTime":"0","summary":"BRIEF-Tetratherix Says BioOptix Enters Agreement With Alcon ResearchDec 1  - Tetratherix Ltd TTX.AX:BIOOPTIX ALCON UPDATEBIOOPTIX ENTERS AGREEMENT WITH ALCON RESEARCHALCON TO PROVIDE MILESTONE-BASED DEVELOPMENT FUNDING TO COMPLETE RANGE OF SPECIFIC PRECLINICAL STUDIESFurther company coverage: TTX.AX ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251201:nTUE9FLZQW:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7067","TTX.AU"],"gpt_icon":0},{"id":"2588713744","title":"Tetratherix Ltd-Biooptix Alcon Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2588713744","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588713744?lang=en_us&edition=fundamental","pubTime":"2025-12-01 05:29","pubTimestamp":1764538194,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251130:nTUE9FLZQW:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["TTX.AU","BK7067"],"gpt_icon":0},{"id":"2588130317","title":"Tetratherix - Alcon to Provide Milestone-Based Development Funding to Complete Range of Specific Preclinical Studies","url":"https://stock-news.laohu8.com/highlight/detail?id=2588130317","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588130317?lang=en_us&edition=fundamental","pubTime":"2025-12-01 05:29","pubTimestamp":1764538194,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251130:nTUE9FLZQW:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["TTX.AU","BK7067"],"gpt_icon":0},{"id":"2578946176","title":"Tetratherix Says Second Phase of Hydrogel Spacer First In-Human Clinical Investigation Underway","url":"https://stock-news.laohu8.com/highlight/detail?id=2578946176","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2578946176?lang=en_us&edition=fundamental","pubTime":"2025-10-27 14:40","pubTimestamp":1761547208,"startTime":"0","endTime":"0","summary":"Tetratherix  said the second stage of the TUTELA trial, a first in-human clinical investigation of the Tutelix hydrogel spacer, was initiated and patient recruitment is underway, according to a Monday Australian bourse filing.Its Tegenix bone regeneration animal study implantation began, and the US Food and Drug Administration submission timing remains on track, it added.Its TegenEOS animal study implementation is planned for the second quarter of fiscal year 2026.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["TTX.AU","BK7067"],"gpt_icon":0},{"id":"2575239502","title":"Tetratherix Says Safety Review Committee Confirms No Procedural Related Adverse Events at Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2575239502","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2575239502?lang=en_us&edition=fundamental","pubTime":"2025-10-14 07:00","pubTimestamp":1760396438,"startTime":"0","endTime":"0","summary":"Tetratherix  said a Safety Review Committee confirmed that, to date, no procedural related adverse events were reported from the first patients, who were implanted with the company's Tutelix spacer, a device to reduce side effects from radiation therapy in prostate cancer, according to a Tuesday filing with the Australian bourse.The prostate remained visible during the insertion of the spacer, which formed a hydrogel structure at the intended site, the filing said.The presence of the spacer minimised the high dose received, and the size and the structure of the spacer remained unchanged during the treatment period, the filing added.Patient recruitment is now underway for stage two of the company's Tutela trial, the company said.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["TTX.AU","BK7067"],"gpt_icon":0},{"id":"2575385235","title":"Tetratherix Ltd-Tutela Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2575385235","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2575385235?lang=en_us&edition=fundamental","pubTime":"2025-10-14 05:42","pubTimestamp":1760391772,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251013:nTUE5W41V1:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7067","TTX.AU"],"gpt_icon":0}],"pageSize":20,"totalPage":1,"pageCount":1,"totalSize":15,"code":"91000000","status":"200"}]}}